ISTP, 4901 Searle Parkway, Skokie, Il 60077

Vetter’s Chicago Site Wins Award

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), announced that its US clinical manufacturing facility located at the Illinois Science+Technology Park in Skokie has been named as one of “Chicago’s Best and Brightest Companies to Work For®”.

The award, sponsored by the National Association for Business Resources, recognizes only those companies that have distinguished themselves as having the most innovative and thoughtful human resources approach. An independent research firm evaluates each company’s entry based on key measures in various categories which include among others, Compensation; Benefits and Employee Solutions; Employee Enrichment; Work-Life Balance; Communication and Shared Vision; Diversity and Inclusion, and Community Initiatives.

“Vetter is thrilled to be recognized for our efforts, particularly since the key parameters for deciding award winners are those of critical importance to our employees,” said Dr. Susanne Lemaine, President Vetter Development Services USA Inc. “This recognition reflects our ongoing efforts to perform consistently at a high level for our customers and to be an attractive company to work for in Chicago.”

Jennifer Kluge, President and CEO, Best and Brightest Programs said “..these companies rise to the challenge through their cultural innovation by maximizing their workforce potential.” .

To read the entire release, click here.

Comments Off on Vetter’s Chicago Site Wins Award Blog, News

Read more

Vetter’s Skokie Facility Expansion nears Completion

Since beginning full operations in late 2011, Vetter’s US early-stage development site has been expanding to help meet growing customer demands.  A significant level of expansion activities are nearing completion at its US clinical manufacturing facility located at the Illinois Science & Technology Park. The ongoing growth of the facility will help satisfy existing and ever-increasing future customer requirements as well enable meet the complex needs of newer drug molecules like peptides or antibodies, many which need refrigeration or freezing. New offices with 45 work stations, conference rooms and an archive room are also included. To support the increase in customer projects, a permanent second work shift will be added in Visual Inspection over the next months. A second shift in Quality Oversight is also planned.

“This variety of activities is a further proof point of Vetter’s consistent strategic approach to stay ahead of the market by focusing on the important service needs of our customers during their drug development journey; promptness; flexibility; high yield of their valuable API and, of course high quality,” explains Dr. Claus Feussner, Senior Vice President of Vetter Development Service.  For more details, click here to access the entire press release. 

With the new additions, most of which are expected to be completed by April, the site will increase its storage space by an additional 3,100 sq. ft. The new storage includes a 2,500 sq. ft. freezer farm as well as a planned 600 sq. ft. walk-in refrigerator. In total, 6,800 sq. ft. of storage space will result. A second extension, now in the final planning stage, will include an additional 1,500 sq. ft. of room temperature and freezer space. “When completed, the facility will have more than double the overall storage space we have currently available. This extensive expansion of freezer and refrigeration storage space represents the ongoing evolution in our Chicago business,” summarizes Dr. Susanne Lemaine, Vice President Vetter Development Service Chicago.

For an overview of the history of Vetter, click here. 

Comments Off on Vetter’s Skokie Facility Expansion nears Completion Blog, News

Read more

Vetter – Current Market Developments

Increasingly, contract development and manufacturing organizations (CDMOs) like Vetter are acting as the interface between small biotech firms and large drug manufacturers

Flexibility, responsiveness and operational excellence are being demanded by drug developers. The challenge faced by companies like Vetter Pharma International is to deliver these to customers. Oskar Gold, notes that Vetter believes that partnership is always the key to success, with operational excellence being decisive in both the development and commercial phases.

“Particularly in the early drug development phases, a number of issues that can affect the entire development project scope can arise and thus flexibility is critical,” Gold says. “Also, it is important that a sponsor and service provider with a common target in mind act as one to successfully perform a drug development project that can get the drug on the market as fast as possible, where it can improve or even save patient lives.”

Listen to the video interview with Oskar Gold of Vetter discussing current market developments and their multifaceted impacts.

Comments Off on Vetter – Current Market Developments News

Read more